Flower

Studies reveal that Women can dodge Breast Cancer at an early stage

by Marshaneil Soumi D'Rozario |16 August, 2018

studies reveal that women can dodge breast cancer at an early stage
 Image used for representational purpose only

Women suffering from breast cancer at an early stage can circumvent the agony of chemotherapy. Nearly, 70% of breast cancer patients are likely to benefit under a new precision medicine approach. Breast cancer is the most common cancer in women in India and accounts for 27% of all cancers in women.  At an incidence rate of 25.8 per 100,000, it is lower than in some developed countries, but the mortality rate (12.7 per 100,000) is comparable to that in western countries. Data on incidence rates of breast cancer from six major cancer registries of India show that the annual percentage increase in the incidence of breast cancer has been in the 0.46 to 2.56% range. 

 

Recent path-breaking findings by the landmark Trial Assigning Individualized Options for Treatment (TAILORx) demonstrates the Oncotype DX Breast Recurrence Score® Test definitively identifies the 70% of women with early-stage breast cancer who receive no benefit from chemotherapy, and the 30% of women for whom chemotherapy benefit can be life-saving. The TAILORx study, the largest ever breast cancer treatment trial, was published in the New England Journal of Medicine in June.  It was supported by the United States National Cancer Institute (NCI), part of the National Institutes of Health, and designed and led by the ECOG-ACRIN Cancer Research Group. 

 

Dr. Vijay Anand Reddy, Senior Consultant - Clinical Oncology & Radiotherapy at Apollo Health City, Hyderabad, commented, “I strongly agree with the findings of the study as I believe more in hormonal therapy, which- in most cases- is sufficient. Chemotherapy has more toxicity and minimal benefits. This finding will definitely aid in reducing the unnecessarily administered chemotherapy which is a relief to both the doctors and the patients.”

 

Importantly, 30 percent of early-stage breast cancer patients will derive benefit from chemotherapy, including women of any age with Breast Recurrence Score results of 26 to 100, and in women younger than 50, where a modest (2 percent) benefit from chemotherapy was observed with Breast Recurrence Score results of 16 to 20, which gradually grew as scores increased up to and above 25. This important finding reveals a new level of precision of chemotherapy benefit for younger patients that only the Oncotype DX® test can provide.

 

"The TAILORx findings can spare thousands of women from getting toxic chemotherapy treatment that really wouldn’t benefit them.  By identifying the right patients who can benefit from chemotherapy, and sparing chemotherapy and its toxic side effects in those who will not benefit from its treatment, the personalized treatment approach is a breakthrough advancement in the medical fraternity.  As the sole commercial representative in India for Genomic Health, we hope to bring changes in the standard of care in India," said Mr. Prasad Vaidya, CEO, Medilinks Inc. 

 

To more precisely define the effect of chemotherapy for women considered to be at intermediate risk for recurrence, 6,711 women with Oncotype DX Breast Recurrence Score results of 11 to 25, the primary study group in TAILORx, were randomized to receive endocrine therapy with or without chemotherapy. These randomized patients comprised two-thirds of all patients enrolled in TAILORx and were followed by the investigators for approximately nine years on average.

 

“This is a brilliantly executed study with a well-represented sample of patients. The only drawback of Oncotype DX Breast Recurrence Score® Test mentioned in the study is that it is an expensive test- costing around Rs.2.75 lakh- which makes it less affordable in India. The Oncotype Dx test helps in identifying high risk patients who will benefit with chemotherapy. Results of the TAILORx study showed that 70% of most common type of breast cancer did not benefit with chemotherapy. Only hormonal therapy, with fewer side effects is enough to cure more than 90% of these patients. The test makes clear distinction which will help in avoiding chemotherapy and side effects to a large number of patients,” said Dr. P. S. Dattatreya, Sr. Consultant Medical Oncologist, Omega Hospitals, Hyderabad.

 

Dr. Suresh Advani, a renowned oncologist, and Padma Bhushan recipient concluded, “Today, personalized medicine has allowed us to avoid chemotherapy for certain group of patients. We can select the people who don’t need chemo and administer it to only those who need it.” 


 Disclaimer: Welthi.com does not guarantee any specific results as a result of the procedures mentioned here, and the results may vary from person to person. Read more
KIMS Cuddles Announces ‘Cuddles Mrs. Mom Contest’ for Pregnant Women

KIMS Cuddles Announces ‘Cuddles Mrs. Mom ...

There is no better feeling than the movement of li...
PINK RIBBON CAMPAIGN 2018 CELEBRATING ELEVEN POSITIVELY EVENTFUL YEARS

PINK RIBBON CAMPAIGN 2018 CELEBRATING ELEVEN ...

SPORTING TOURNAMENT IN SUPPORT OF BREAST CANCER AW...
L V Prasad Eye Institute’s Rural Eye Care Program celebrates 20 years of work

L V Prasad Eye Institute’s Rural Eye Care ...

Coincides with the 2018 International Agency for t...
Manipal Hospitals Signs Cricket Legend Rahul Dravid As The Brand Ambassador

Manipal Hospitals Signs Cricket Legend Rahul ...

Manipal Hospitals, one of India’s leading health...
Bangladeshi senior citizen survives life threatening abdominal aortic aneurysm at Fortis Malar

Bangladeshi senior citizen survives life ...

Swollen abdominal aorta with multiple angulation's...
Aware Gleneagles Global Hospitals launches ‘I AM EMERGENCY READY’ campaign in Hyderabad

Aware Gleneagles Global Hospitals launches ‘I ...

Aware Gleneagles Global Hospitals Hyderabad launc...
Hyderabad Doctors successfully perform Asia's First Transcatheter Tricuspid Valve Replacement procedure

Hyderabad Doctors successfully perform Asia's ...

Only 40 such surgeries reported around the world...
SuVitas Launches Bangalore’s First Dedicated Transition Care Facility

SuVitas Launches Bangalore’s First Dedicated ...

Catering to a need for post critical care that has...
Itermittent Fasting: The How s and Why's

Itermittent Fasting: The How s and Why's

Intermittent Fasting is the latest global fitness ...
Our responsibility to our emotions

Our responsibility to our emotions

In this world, there are all kinds of people. Some...
Stop drowsing while driving

Stop drowsing while driving

A long spell of work or drive can lead to physical...
Eyes show you the world

Eyes show you the world

With increasing rate of air pollution, the ways it...